Solstice Oncology $225M Series A Launch
Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 11, 2026
The launch and large Series A financing signal continued strong investor appetite for differentiated immuno-oncology assets, supporting valuations across the early-stage biotech sector. Harbour BioMed gains validation of its antibody platform and a partner to fund global development of porustobart, potentially improving its pipeline outlook and licensing revenue prospects.
Solstice Oncology, a clinical-stage immuno-oncology company focused on neoadjuvant cancer treatment, launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion Ventures and other investors. The company is advancing porustobart, a second-generation Fc-enhanced CTLA-4 antibody discovered and developed by Harbour BioMed, across two clinical indications, beginning with microsatellite-stable clinical stage II-III colon cancer. A Phase 2 trial evaluating porustobart in combination with pembrolizumab in the neoadjuvant setting will open for enrollment early in the fourth quarter of 2026, with data anticipated in the second half of 2027. In February 2026, Harbour BioMed entered into a license agreement and equity partnership with Solstice Oncology granting exclusive development and commercialization rights to porustobart outside Greater China. In an earlier Phase 2 study conducted by Harbour BioMed, porustobart combined with tislelizumab demonstrated a 30% objective response rate (7 of 23 patients) in late-line MSS metastatic colorectal cancer patients without liver metastases, with a median duration of response of 8.4 months and a favorable safety profile. Solstice Oncology is led by CEO Caroline Loew, while Harbour BioMed is led by Founder, Chairman and CEO Jingsong Wang. RA Capital Partner Josh Resnick and University of Leeds Professor Jenny Seligmann commented on the potential of the neoadjuvant approach.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard